Sort by
Refine Your Search
-
Listed
-
Country
-
Employer
- ;
- Nature Careers
- University of Cambridge
- University of Pittsburgh
- Aston University
- Brunel University
- California Institute of Technology
- Forschungszentrum Jülich
- Heidelberg University
- National Institute for Bioprocessing Research and Training (NIBRT)
- Technical University of Denmark
- Technical University of Munich
- The Ohio State University
- The University of Chicago
- The University of Iowa
- University College Cork
- University of California, Berkeley
- University of Central Florida
- University of Luxembourg
- University of Massachusetts Medical School
- University of Miami
- University of Michigan
- University of Nebraska Medical Center
- University of Newcastle
- University of Nottingham
- University of Utah
- 16 more »
- « less
-
Field
-
modern Bayesian modelling frameworks such as Stan, Turing.jl, and PyMC, including automatic differentiation frameworks, MCMC sampling algorithms, and iterative Bayesian modelling. Special attention will be
-
Bayesian methods, deep learning, deep generative models, reinforcement learning, graph neural networks. Interviews are expected to happen in July 2025. Applicants are encouraged to guarantee that referees
-
of senior researchers and will perform research necessary to fulfil the objectives of the Project Identification of therapeutic targets in MNX1-rearranged infant Acute Myeloid Leukaemia, externally sponsored
-
deacetylases, including SIRT1 and HDAC6, and ion channels to control signaling pathways impacting metabolism, apoptosis, and autism, and we leverage these discoveries to develop targeted therapeutic strategies
-
, metastasis, functional genomics, therapeutic target development, and cancer proteomics. Submit a full-length CV, a 3-page future research plan, and the names and contact for 3-5 references Required
-
) representation (Research Field “Staging Enmity")and (3) physical encounters (Research Field “Enemy Contact”). Our research regions include Europe, Asia and the Middle East. The RTG Ambivalent Enmity targets
-
pathobiology of leukemia, including acute myeloid leukemia (AML) and T cell acute lymphoblastic leukemia (T-ALL), as well as the discovery and validation of new therapy targets to treat relapsed/refractory AML
-
their therapeutic potential both in vitro and in vivo that includes designing CRISPR-Cas targeting strategies, analyzes editing outcomes on a molecular level using next gen sequencing and ddPCR and conducts
-
developing next-generation antimicrobial peptide (AMP)-based solutions targeting vaginal fungal infections, particularly Recurrent Vulvovaginal Candidiasis (RVVC). The project combines microbiology, molecular
-
Research Assistant/Research Associate* in Cardiovascular Epidemiology (BHF Scholarship) (Fixed Term)
understanding of aetiology and link to therapeutic target prioritization efforts. Therapeutic target prioritization: prioritizing potential therapeutic targets for CVDs to help reduce unsustainable high failures